Clinical trials: Eosinophilic Gastroenteritis
Eosinophilic Esophagitis
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label…
- Trial name
- NCT02098473
- Testing
- RPC4046
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Celgene
Eosinophilic Esophagitis
Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis
The proposed Phase 1b study design was a randomized, placebo-controlled, double-blind, study to evaluate the safety and pharmacokinetics of oral BT-11 in active eosinophilic esophagitis.
- Trial name
- NCT04835168
- Testing
- BT-11 low, BT-11 high
- Sponsor
- NImmune Biopharma
Eosinophilic Gastritis, Eosinophilic Duodenitis
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002), given monthly for 6 doses, in patients with moderately to severely active Eosinophilic…
- Trial name
- ENIGMA 2 (NCT04322604)
- Testing
- lirentelimab (AK002)
- Where
- 60 sites in United States
- Volunteers
- 181 people
- Sponsor
- Allakos Inc.
Eosinophilic Esophagitis
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
This is a 2-part randomized, double-blind, placebo-controlled study followed by an open-label extension (OLE) of APT-1011 in adults with EoE.
- Trial name
- FLUTE-2 (NCT04281108)
- Testing
- APT-1011, Esophagogastroduodenoscopy
- Where
- 56 sites in United States, Australia and 1 more
- Volunteers
- 143 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
This trial will study three doses of reslizumab versus placebo in children with eosinophilic esophagitis (EE). The objectives of the trial will be to study the effectiveness of reslizumab in improving the clinical signs and…
- Trial name
- NCT00538434
- Testing
- Reslizumab, Saline
- Where
- 37 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Ception Therapeutics
Eosinophilic Esophagitis (EoE)
An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
This is a multicenter, double- blind extension study of Oral Budesonide Suspension (OBS) in adults and adolescents (11 to 55 years of age, inclusive) with Eosinophilic Esophagitis (EoE) who have completed participation in the…
- Trial name
- ORBIT2 (NCT02736409)
- Testing
- Oral Budesonide Suspension (OBS)
- Where
- 62 sites in United States
- Volunteers
- 219 people
- Sponsor
- Shire
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD)
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD).
- Conditions
- Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
- Trial name
- ENGAGE (NCT05831176)
- Testing
- Dupilumab
- Where
- 53 sites in United States, Canada and 2 more
- Volunteers
- 22 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis.
- Trial name
- EoDyssey (NCT04856891)
- Testing
- AK002
- Where
- 39 sites in United States
- Volunteers
- 94 people
- Sponsor
- Allakos Inc.
Eosinophilic Esophagitis
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal symptoms.
- Trial name
- FLUTE (NCT03191864)
- Testing
- APT-1011
- Where
- 75 sites in United States, Belgium and 4 more
- Volunteers
- 106 people
- Sponsor
- Adare Pharmaceuticals, Inc.
Eosinophilic Esophagitis
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an open-label extension (OLE) in adolescents (≥12 to <18 years) with EoE.
- Trial name
- FLUTEEN (NCT05083312)
- Testing
- APT-1011
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538.
- Trial name
- NCT04991935
- Testing
- CC-93538
- Where
- 167 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Celgene
Eosinophilic Gastritis, Eosinophilic Duodenitis
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of subcutaneous lirentelimab (AK002), given monthly for 6 doses, in…
- Trial name
- ENIGMA-SC (NCT05152563)
- Testing
- AK002
- Where
- 76 sites in United States
- Sponsor
- Allakos Inc.
Eosinophilic Esophagitis
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in…
- Trial name
- EOS-4 (NCT06596252)
- Testing
- Budesonide
- Where
- 21 sites in United States, Spain
- Volunteers
- 308 people
- Sponsor
- Dr. Falk Pharma GmbH
Eosinophilic Esophagitis
Proof of Concept Study of OC000459 in Eosinophilic Esophagitis
This will be a randomised, double blind, placebo controlled, parallel group evaluation of the effect of OC000459 given orally for eight weeks on active eosinophilic esophagitis.
- Trial name
- NCT01056783
- Testing
- OC000459
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- Oxagen Ltd
Eosinophilic Esophagitis (EoE)
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study.
- Trial name
- NCT03245840
- Testing
- Budesonide oral suspension
- Where
- 45 sites in United States
- Volunteers
- 133 people
- Sponsor
- Shire
Eosinophilic Esophagitis (EoE)
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding…
- Trial name
- EoE-TOTs (NCT07112378)
- Testing
- dupilumab
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
This is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with…
- Trial name
- ProMEAL (NCT06695897)
- Testing
- Dupilumab
- Where
- 15 sites in Germany
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi
Eosinophilic Esophagitis (EoE)
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)
- Trial name
- NCT01642212
- Testing
- Oral Budesonide Suspension (MB-9)
- Where
- 23 sites in United States
- Volunteers
- 93 people
- Sponsor
- Shire
Eosinophilic Esophagitis
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension.
- Trial name
- NCT05634746
- Testing
- APT-1011, Esophagogastroduodenoscopy
- Where
- 60 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome